| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.055 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | sotrastaurin | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.3 |